83 results about "Bronchitis copd" patented technology

The invention belongs to the field of veterinary drugs, and relates to an avian infectious bronchitis virus antigen recombinant protein S-Trimer and a subunit vaccine thereof. The invention provides an avian infectious bronchitis virus antigen recombinant protein S-Trimer. The amino acid sequence of the antigen recombinant protein S-Trimer is as shown in SEQ ID No. 4. The invention provides an infectious bronchitis virus antigen. The infectious bronchitis virus antigen is of a trimer structure of the recombinant protein S-Trimer. The invention provides a chicken infectious bronchitis virus subunit vaccine. The subunit vaccine comprises a pharmaceutically acceptable carrier and an immune dose of the chicken infectious bronchitis virus antigen. The vaccine is high in safety, good in immunogenicity and stable in batches, and can provide complete protection for attacking the infectious bronchitis virus.

The invention discloses a primer for detecting and distinguishing genotypes of avian infectious bronchitis viruses and application, and belongs to the technical field of biological detection. The primer combination comprises a universal primer and a probe group I for detecting an IBV total group, a specific primer and a probe combination II for detecting a GI-19 genotype, and a specific primer and a probe combination III for detecting a GVI-1 genotype, and nucleotide sequences are respectively shown as SEQ ID NO.1-9; different fluorophores are respectively marked at 5'ends of each group of probes, and corresponding quenching groups are marked at 3 'ends of each group of probes. The primer combination provided by the invention has high specificity and high sensitivity, rapid detection of the IBV and accurate distinguishing of main epidemic genotypes (GVI-1 and GI-19) can be completed in a single reaction, complex sequencing and analysis steps in a traditional method are omitted, the detection efficiency is greatly improved, and the primer combination has a good application prospect. And a convenient tool is provided for farm epidemic situation monitoring and clinical diagnosis.

The invention discloses a compound for regulating the activity of micro RNA-124, the compound has a structure as shown in a formula (I), and the compound can be used for preventing or treating inflammatory diseases. Comprising but not limited to inflammatory bowel disease, rheumatoid arthritis, Crohn's disease, ulcerative colitis, multiple sclerosis, Alzheimer's disease, Paragins disease, osteoarthritis, atherosclerosis, ankylosing spondylitis, psoriasis, dermatitis, Sjogren syndrome, bronchitis, asthma and inflammation associated with colon cancer; the compounds are useful for treating colon cancer, and in particular inflammatory bowel disease, rheumatoid arthritis, Crohn's disease, ulcerative colitis, multiple sclerosis, osteoarthritis, ankylosing spondylitis, psoriasis, Sjogren syndrome, bronchitis, and inflammation associated with colon cancer.

This invention discloses the application of Akkermansia in the preparation of drugs for the prevention and treatment of avian infectious bronchitis virus (AIB). Through research, this invention has found that Akkermansia can improve the survival rate of chickens infected with AIB and inhibit the replication of AIB. This demonstrates that Akkermansia has important applications in the preparation of drugs for the prevention and / or treatment of AIB infection, providing a new solution for the treatment of AIB infection, and can be specifically applied in drugs or feed additives for combating AIB infection.

This invention discloses a traditional Chinese medicine composition for preventing and treating inflammatory diseases in animals, its preparation method, and its application, belonging to the field of traditional Chinese medicine composition technology. The raw materials of this traditional Chinese medicine composition for preventing and treating inflammatory diseases in animals, by mass percentage, include 8%-12% extract of honeysuckle branches and leaves, 8%-12% extract of dipsacus root, 8%-12% chrysanthemum, 4%-6% mulberry leaves, 4%-6% licorice root, 0.8%-1.2% peppermint, and 50.8%-67.2% anhydrous glucose. It has good anti-inflammatory effects and can effectively alleviate inflammatory responses caused by LPS. In particular, it has good therapeutic and ameliorative effects on the clinically prevalent porcine reproductive and respiratory syndrome (PRRS) and infectious bronchitis in chickens, effectively reducing morbidity and mortality, and improving production performance.

The present application belongs to the field of veterinary medicine, and specifically discloses a traditional Chinese medicine composition for preventing and treating chicken infectious bronchitis, a preparation method and application thereof. The traditional Chinese medicine composition is composed of the following raw materials in parts by weight: Ephedra 12 parts, apricot kernel 12 parts, licorice 9 parts, coix seed 30 parts, forsythia 12 parts, honeysuckle 20 parts, white eupatorium 12 parts, smilax 20 parts, and purple violet 6 parts. The composition can be used for preventing and treating artificially infected IBV chicks, and can significantly improve the survival rate of chicks, alleviate the decrease in body weight growth caused by IBV, relieve clinical symptoms, reduce the viral load in trachea and kidney tissues, reduce organ pathological damage, and promote the recovery of the body. The traditional Chinese medicine composition for preventing and treating chicken infectious bronchitis is easy to obtain, rich in resources, low in cost, safe, non-toxic and non-residual, and the preparation method is simple and suitable for large-scale production.

Disclosed is a synthetic, non-naturally occurring 12-amino acid peptide, Lung-specific Targeting Peptide, belonging to the larger class of cell penetrating peptides, for delivery of both diagnostic and potentially therapeutic agents to the lung. Also disclosed are methods of treating pulmonary disease, e.g., chronic obstructive pulmonary disease (COPD), emphysema, chronic bronchitis, asthma, primary ciliary dyskinesia (PCD), cystic fibrosis (CF), and lung cancer.

The invention belongs to the technical field of poultry disease prevention and treatment, and discloses application of a rhizoma kaempferiae extract in preparation of a medicine for resisting avian infectious bronchitis virus. The rhizoma kaempferiae extract is prepared by taking rhizoma kaempferiae as a raw material and ethanol as an extraction solvent through extraction, filtration and concentration. Experimental results show that the rhizoma kaempferiae extract has no obvious toxicity to chick embryos within a certain dosage range; after the chicken embryo is infected with the infectious bronchitis virus, the survival rate of the chicken embryo can be improved by treating the chicken embryo with different doses of the rhizoma kaempferiae extract, and the rhizoma kaempferiae extract can reduce the virus antigen expression level and virus copy number in the liver tissue and allantoic fluid of the chicken embryo, so that the chicken embryo has prevention and treatment effects on infectious bronchitis virus infection. The rhizoma kaempferiae extract has the advantages of easily available raw materials, simple process and low cost, and is suitable for popularization and application.

The invention relates to an infectious bronchitis subunit vaccine based on a nano-skeleton technology. Specifically, the invention provides a fusion protein which sequentially comprises an infectious bronchitis virus S protein fragment or a mutant thereof, a connecting peptide and helicobacter pylori ferritin from an N terminal to a C terminal, wherein the infectious bronchitis virus S protein fragment is S1 protein, and the amino acid sequence of the S protein fragment is as shown in SEQ ID NO. 2; the mutant of the chicken infectious bronchitis virus S protein fragment is S1-2 protein or S1-3 protein, the amino acid sequence of the S1-2 protein is shown as SEQ ID NO.4, and the amino acid sequence of the S1-3 protein is shown as SEQ ID NO.5. The invention further discloses a preparation method of the chicken infectious bronchitis virus S protein fragment.

The application discloses a kind of avian influenza and avian infectious bronchitis two-union recombinant subunit vaccine and its preparation method and application.The recombinant protein is by replacing the head domain of AIV HA protein with the RBD domain of IBV S protein, while adding GCN4, Trimer-tag trimer tag in sequence, the recombinant protein obtained, the recombinant protein is expressed in vitro using insect cells and prepared into subunit vaccine.The vaccine prepared by the application can produce high-level neutralizing antibodies against homologous and heterologous H9N2 subtype avian influenza virus after immunizing chicken population, while significantly reducing the virus discharge level and the histopathological changes caused, and can also induce high-level specific antibodies and neutralizing antibodies against QX subtype avian infectious bronchitis virus, effectively inhibit discharge, viral load, and reduce tissue lesions.The application does not depend on chicken embryo, and has low production cost and short cycle, and can simultaneously prevent avian influenza and avian infectious bronchitis.

1. The name of the design product: water negative ion device. 2. The use of the design product: for air purification and disinfection, auxiliary treatment of chronic bronchitis and non-acute insomnia. 3. The design points of the design product: in shape. 4. The picture or photo that best indicates the design points: perspective drawing.

The invention provides a QX type avian infectious bronchitis virus mRNA vaccine and application thereof. The gene sequence of the mRNA vaccine molecule is shown as SEQ ID NO.9 or SEQ ID NO.13. The invention also provides a preparation method of the QX type avian infectious bronchitis virus mRNA vaccine. The preparation method of the QX-type avian infectious bronchitis virus mRNA vaccine molecule provided by the invention is simple to operate, preparation can be performed only by knowing a gene sequence, and compared with an inactivated vaccine, the production price is low, and the dosage is small; compared with attenuated live vaccines, the vaccine is short in production period and safe.

Apparatuses, systems and methods are provided for treating pulmonary tissues via delivery of energy, generally characterized by high voltage pulses, to target tissue using a pulmonary tissue modification system (e.g., an energy delivery catheter system). Example pulmonary tissues include, without limitation, the epithelium (the goblet cells, ciliated pseudostratified columnar epithelial cells, and basal cells), lamina propria, submucosa, submucosal glands, basement membrane, smooth muscle, cartilage, nerves, pathogens resident near or within the tissue, or a combination of any of these. The system may be used to treat a variety of pulmonary diseases or disorders such as or associated with COPD (e.g., chronic bronchitis, emphysema), asthma, interstitial pulmonary fibrosis, cystic fibrosis, bronchiectasis, primary ciliary dyskinesia (PCD), acute bronchitis and / or other pulmonary diseases or disorders.

A novel infectious bronchitis virus (IBV) serotype, to isolated attenuated IBV strains derived therefrom, and to live or inactivated vaccines against infectious bronchitis made using the isolated attenuated IBV strain.

The invention relates to a quadruple fluorescent PCR (Polymerase Chain Reaction) primer probe combination and a kit for an infectious bronchitis virus. The invention belongs to the field of biology, and discloses a quadruple fluorescent PCR (Polymerase Chain Reaction) primer probe combination for GI-13 / GI-19 / GVI-1 typing and general detection of an infectious bronchitis virus. Comprising a first primer probe combination for distinguishing an infectious bronchitis virus from other viruses, a second primer probe combination for identifying a GI-13 type infectious bronchitis virus, and a third primer probe combination for identifying a GI-19 type infectious bronchitis virus, and the fourth primer probe combination is used for identifying the GVI-1 type avian infectious bronchitis virus. The PCR primer probe combination is suitable for an RT-qPCR detection system, and can be used for effectively distinguishing GI-19, GI-13 and GVI-1 type IBV viruses; meanwhile, the invention further discloses a kit.

The invention provides a construction method and application of a chicken fallopian tube embolism model, and belongs to the technical field of animal infection models. The invention provides a construction method of a chicken fallopian tube embolism model based on multi-pathogen infection. The mycoplasma synoviae, the infectious bronchitis virus and the riemerella anatipestifer are utilized to infect the chicken, and the clinical typical salpingemphasis pathological process including cheese-like substance accumulation in a salpingemphasis cavity, serious abdominal air sacculitis complications and related tissue inflammation changes can be accurately reproduced. The model constructed by the invention is high in morbidity, and is suitable for epidemic disease pathogenesis research, drug screening and vaccine potency test. Compared with an existing single pathogen infection model, the model is closer to a clinical reality multi-pathogen cooperative infection scene, and the blank of a standardized multi-pathogen mixed infection induced fallopian tube embolism animal model is filled up.

The invention discloses a Tibetan medicine Banjiaojiaopian pellet preparation, which comprises raw materials and auxiliary materials, the raw materials comprise the following components: gentiana algida, agilawood, choerospondias axillaris, white sandalwood, myristica fragrans, tabasheer, alpine horseradish, costus root, fructus chebulae, fructus terminaliae billericae, emblic leafflower fruit, tinospora sinensis merr, corydalis impatiens, clove and liquorice, and the auxiliary materials comprise an adhesive and a filler microcrystalline cellulose; the technological parameters for preparing the pellet preparation by adopting centrifugal granulation are as follows: the liquid spraying speed is 50ml / min, the number of revolutions of a turntable is 30r / min, and the air inlet temperature is 75 DEG C. Compared with traditional pills, the pellet preparation provided by the invention has the advantages of high dissolution rate, obviously improved bioavailability, reliable drug effect, accurate taking dosage, stable quality, low cost, good treatment effect, fine production process, good reproducibility, good quality controllability, high industrial production efficiency and wide application range.

The present disclosure relates to methods of treatment of asthma, COPD, Asthma-COPD Overlap Syndrome (ACOS), and chronic bronchitis, or a combination thereof, with formulations comprising (S)-3-(3-(1-methyl-2-oxo-5-(pyrazolo[1,5-a]pyridin-3-yl)-1,2-dihydro-3H-imidazo[4,5-b]pyridin-3-yl)piperidin-1-yl)-3-oxopropanenitrile.

Provided are a Hedera helix extract, a preparation method therefor, and use thereof. The preparation method comprises extracting Hedera helix leaves with 75%-85% ethanol, concentrating, adjusting the pH value to 9.5-11, standing, filtering to obtain a crude extract, passing the crude extract through a chromatographic column, and eluting with 60%-80% ethanol to prepare the Hedera helix extract. The chromatographic column is an HPD100 macroporous resin column, a polyamide column or a C18 column. The Hedera helix extract can be used for preparing drugs with anti-inflammatory, expectorant, and antitussive effects, as well as for treating acute bronchitis.

The invention provides a six-joint inactivated vaccine for poultry as well as a preparation method and application of the six-joint inactivated vaccine, and belongs to the technical field of veterinary vaccines. The six-combined inactivated vaccine for poultry is prepared from an inactivated newcastle disease virus antigen concentrated solution, an inactivated infectious bronchitis virus antigen concentrated solution, an inactivated H3 subtype avian influenza virus antigen concentrated solution, an inactivated H9 subtype avian influenza virus antigen concentrated solution, an inactivated I-group 4-type avian adenovirus solution, an inactivated H3 subtype avian influenza virus antigen concentrated solution, an inactivated H3 subtype avian influenza virus antigen concentrated solution, an inactivated H3 subtype avian influenza virus antigen concentrated solution, an inactivated H3 subtype avian influenza virus antigen concentrated solution and an inactivated H3 subtype avian influenza virus antigen concentrated solution. The inactivated avian infectious laryngotracheitis virus gD protein liquid is pretreated, then mixed according to a step-by-step mixing method and emulsified, and the chicken infectious laryngotracheitis virus gD protein liquid is prepared. According to the vaccine, through the innovative preparation process and technical means, the optimization of the antigen proportion and the mixing sequence and the adjustment of reaction environment parameters, the structural change or antigenicity reduction caused by the interaction between antigens is effectively avoided, the stable and effective structure of each antigen in the vaccine can be ensured, and finally the immune effect of the vaccine is not influenced.

DEPCT64 This invention relates to 4 / 91IBV (Infectious Bronchitis Virus) which is coded for... Heterologous S (spike) protein or fragments thereof; furthermore, this invention also... This is related to the components that elicit an immune response, which include the aforementioned 4 / 91IBV. Process the code for heterologous S (spike) protein or fragments thereof. This invention also relates to a method for immunizing targets, which includes: Providing the target with an element that induces an immune response to this invention. Furthermore, this invention relates to methods for treating or preventing clinical symptoms caused by IBV. The necessary objectives involve a method of providing the target with the required quantity. The therapeutic efficacy of the immune response-inducing components according to this invention. -----------------------------------------------------------

Disclosed in the present invention are a dimethylphosphoryl substituted compound, and a preparation method therefor, a pharmaceutical composition thereof and the use thereof. Provided in the present invention is a compound of formula (I) or a pharmaceutically acceptable salt thereof. The compound of the present invention can target a host eIF2α kinase, eIF2α phosphorylation and protein synthesis. The compound of the present invention has great biological activity for treating breast cancer. Particularly, compound SIPI-27 and compound SIPI-28 of the present invention has inhibitory activity against breast cancer significantly superior to that of the control compounds BTdCPU and neratinib; and / or the compound of the present invention also has biological activity against coronaviruses and / or orthopoxviruses, in particular, compound SIPI-25 of the present invention has broad-spectrum anti-coronavirus activity against porcine epidemic diarrhea virus (PEDV), mouse hepatitis virus (MHV), infectious bronchitis virus (IBV) and porcine deltacoronavirus (PDCoV), and also has activity against the Taterapox virus (TTV) orthopoxvirus.

The application discloses application of triacetylandrographolide and a composition thereof in preparation of a medicine for relaxing airway smooth muscle, and belongs to the technical field of medicines. In view of the problems of obvious side effects and narrow treatment window of existing medicines, the application finds that triacetylandrographolide (3, 14, 19-Triacetylandrographolide, TAA) and the composition thereof have tracheal relaxation activity, and the triacetylandrographolide and the composition thereof play a relaxation role through non-competitive antagonism of a downstream signal path of a cholinergic receptor. The new mechanism provides a new idea for developing a new bronchial dilator for overcoming drug resistance of existing medicines. The TAA after preparation optimization can be used for treating or preventing airway obstructive diseases such as asthma, chronic obstructive pulmonary disease, bronchitis and acute lung injury.

The invention discloses a children pneumonia course dynamic prediction method based on artificial intelligence, and relates to the technical field of medical information, and the method comprises the steps: S1, determining a perturbation test time window meeting safety conditions according to the current illness state of a child patient and basic ventilation parameters of a respirator, in the time window, the breathing machine executes invasive ventilation according to a preset perturbation ventilation control sequence and keeps the overall oxygenation and ventilation level stable, and meanwhile, an airway pressure waveform, an airflow waveform and an exhaled volume curve output by the breathing machine are continuously collected at a high time resolution; according to the method, a breathing machine perturbation ventilation test, small airway digital twin modeling and disease course scene simulation based on an injury potential energy threshold value are organically combined, and an individualized irreversible small airway remodeling risk field is constructed in the early stage of invasive ventilation of a severe adenovirus pneumonia child patient; therefore, advanced prediction and layered follow-up visit of the occlusive bronchitis after infection are realized.

The invention discloses a medicinal moxa composition for preventing and treating bronchitis and rheumatic arthritis. The medicinal moxa composition comprises platycodon grandiflorum, ginseng, divaricate saposhnikovia root, schizonepeta and moxa. A plurality of volatile active ingredients of the medicinal moxa composition act on a plurality of key targets related to common diseases of bronchitis and rheumatic arthritis through external moxibustion. Composite volatile components released when a medicinal moxa stick prepared from the medicinal moxa composition burns can form a synergistic effect, the traditional Chinese medicine theory of treating an internal illness by external treatment is realized through a lung channel and meridian conduction mechanism, and a new thought and theoretical basis are provided for health care of bronchitis combined with rheumatic arthritis.

The present disclosure relates to methods of treatment of asthma, COPD, Asthma-COPD Overlap Syndrome (ACOS), and chronic bronchitis, or a combination thereof, with formulations comprising (S)-3-(3-(1-methyl-2-oxo-5-(pyrazolo[1,5-a]pyridin-3-yl)-1,2-dihydro-3H-imidazo[4,5-b]pyridin-3-yl)piperidin-1-yl)-3-oxopropanenitrile.

The invention belongs to the technical field of genetic engineering, and particularly relates to an mRNA vaccine based on an infectious bronchitis virus S protein RBD segment. The active ingredient of the vaccine provided by the invention is mRNA (messenger ribonucleic acid) as shown in SEQ ID NO.1 or SEQ ID NO.2. Specific DNA molecules are obtained through a series of sequence design and sequence optimization, specific recombinant plasmids are further obtained, the recombinant plasmids are linearized and recycled and then transcribed into mRNA in vitro, modification such as capping and tailing is carried out, purification is carried out, then mRNA preparation is completed, the mRNA and lipid nanoparticles are mixed and then self-assembled into the lipid nanoparticles loaded with IBV S1-RBD mRNA, and the IBV S1-RBD mRNA lipid nanoparticles loaded with IBV S1-RBD mRNA are obtained. As a novel vaccine, the vaccine can provide a complete protection effect on SPF chickens infected by IBV, and has a good application prospect.

The invention discloses an infectious bronchitis virus strain of which the microbial preservation number is CGMCC (China General Microbiological Culture Collection Center) NO.46468. The vaccine strain has good immunogenicity. The invention also discloses an inactivated vaccine composition taking the virus strain as an immunogen, and a preparation method and application of the inactivated vaccine composition. The vaccine composition has good immunogenicity and immune protection capability.

The invention discloses a primer probe composition for detecting AIV, NDV virulent strains and IBV, a kit and application, and belongs to the technical field of fluorescence detection. The sequence of the primer probe combination is shown as SEQ ID NO.1-SEQ ID NO.9, the primer probe combination comprises a primer pair and a probe for detecting the avian influenza virus, the Newcastle disease virus virulent strain and the avian infectious bronchitis virus, and the primer probe combination can be used for detecting and distinguishing all subtypes of the avian influenza virus and the Newcastle disease virus virulent strain and different genotypes of the avian infectious bronchitis viruses. The kit is high in specificity and sensitivity, does not have cross reaction with other common viruses, and is high in detection sensitivity, and the minimum detectable quantity of the three viruses is 0.8 copy, so that the specific, sensitive and rapid detection of AIV, NDV and IBV can be realized, and the defects of the conventional detection technology are overcome. The method has important practical significance on timely blocking epidemic situation propagation, reducing breeding loss, guaranteeing public health safety and the like.

The invention belongs to the technical field of medicines, and particularly discloses a novel 5-7-5 ring system beta acid compound, a preparation method thereof and application of the compound in preparation of anti-inflammatory drugs. The novel 5-7-5 ring system beta acid compound provided by the invention is obtained by separation in nature for the first time, and can be used for preparing medicines for treating inflammation-related diseases, including but not limited to chronic bronchitis, systemic lupus erythematosus, psoriatic arthritis, retinitis, neurological inflammation, rheumatoid arthritis and the like.